Philips SmartHeart AI Receives FDA Clearance for Cardiac MR Advancements

Philips has achieved a significant milestone with the FDA 510(k) clearance of SmartHeart, an artificial intelligence (AI)-powered cardiac magnetic resonance (MR) planning solution. This innovation aims to simplify the technically demanding process of cardiac MR exams, which are crucial for assessing heart structure and function.

Cardiac MR studies typically require skilled operators to navigate intricate scan planning and manage patient-specific variations. SmartHeart, by integrating AI into the planning workflow, automates these processes within a streamlined, 30-second setup. This automation supports efficient workflows, reduces the workload on technologists, and aims to deliver consistent image quality, making cardiac MR more accessible.

The technology is engineered for reliable performance across various patient anatomies and is capable of automating 14 standard and advanced cardiac views. This efficiency helps minimize operator variability, ensuring that technologists with varying expertise levels can reliably perform cardiac MR procedures.

Ioannis Panagiotelis, PhD, Business Leader at Philips, emphasized the transformative potential of SmartHeart by noting that cardiac MR, though incredibly powerful for heart assessment, has historically been limited in clinical impact by its complexity and the time-intensive nature of the procedure. The integration of SmartHeart into the planning process redefines the execution of cardiac MR exams, effectively turning them into a more streamlined and scalable solution.

From a patient perspective, SmartHeart significantly enhances comfort by potentially reducing the number of required breath holds by up to 75%. This is particularly beneficial for patients with conditions such as dyspnea or anxiety, or for pediatric cases. This feature, combined with the ability to increase throughput without additional staff or equipment, underscores the benefits of the solution.

SmartHeart is a part of Philips' broader suite of AI-enabled cardiac MR solutions, all of which are designed to enhance patient access and improve diagnostic precision. Now authorized for clinical use in the U.S., the suite includes innovations such as CINE FreeBreathing, which facilitates quality imaging without breath-holds, and Cardiac Motion Correction, which addresses both cardiac and respiratory motion to aid in accurate diagnosis.

In light of global cardiac disease trends, expanding access to high-quality cardiac MR exams could lead to earlier disease detection, more accurate diagnoses, and proactive management of heart conditions. Philips' suite, by streamlining the planning process and reducing reliance on operator expertise, aims to enhance productivity in cardiology and radiology departments—without compromising diagnostic quality.